<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01656187</url>
  </required_header>
  <id_info>
    <org_study_id>032011-007</org_study_id>
    <secondary_id>1R01DA029596</secondary_id>
    <nct_id>NCT01656187</nct_id>
  </id_info>
  <brief_title>Attenuation of Corticosteroid Induced Hippocampal Changes</brief_title>
  <official_title>Attenuation of Corticosteroid Induced Hippocampal Changes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if an investigational drug called memantine,used
      here as add-on therapy, is associated with improvements in memory, mood and asthma symptoms.
      We will also examine changes in the brain by taking images or pictures using an MRI/MRS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 50 outpatients receiving chronic oral corticosteroid therapy will be enrolled in a
      52-week randomized, double-blind, placebo-controlled, crossover trial of memantine.
      Participant will receive either memantine or a placebo for 24 weeks. They have an equal
      chance of receiving memantine or placebo. After 24 weeks they will discontinue all study
      medication for 4 weeks. This process will be repeated one additional time in the study and
      the participant will crossed-over to either memantine or placebo, whichever the participant
      did not receive before, so they will have taken both placebo and memantine during one of
      these courses.

      Randomization will be stratified by prednisone dose of &lt; 20 mg/day vs. ≥ 20 mg/day. Memantine
      or placebo starting at 5 milligrams once a day, increased to 5 milligrams twice a day (10
      total) at week 2, 15 milligrams total at week 3, and 20 milligrams total from weeks 4-24
      unless side effects require the study doctor to increase the initial doses slower than
      described above or reduce the dose. This same process will be repeated at week 28 after the
      participant have been completely off of study medication for 4 weeks. Structural MRI and
      1HMRS will be obtained at baseline and weeks 24 and 52 (after memantine and placebo).

      The clinician version of the structured Clinical Interview for DSM-IV (SCID) is a brief
      structured interview for major Axis I disorders in DSM-IV including major depressive
      disorder, dysthymic disorder, bipolar disorders, psychotic disorders, anxiety disorders,
      eating disorders, and alcohol and substance abuse/dependence. This will be given at baseline
      to screen for illnesses with CNS involvement or cognitive impairment. Blood draws will be
      performed at baseline to assess insulin and fasting glucose levels.

      Each participant will then return for follow-up appointments as scheduled and repeat outcome
      measures. Pill counts will be conducted, and a list of current medications and doses will be
      obtained at each visit. Participants will be evaluated by both the RA and PI at each
      follow-up appointment.

      The HVLT-R will be given at baseline, and weeks 12, 24, 28, 40, and 52; this will be the
      primary outcome measure. Other cognitive assessments will be performed at these same visits
      as well.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hopkins Verbal Learning Test-Revised (HVLT-R) Total Score</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Hopkins Verbal Learning Test-Revised (HVLT-R) is a word memory test that contains 12 nouns that are read to a participant for three consecutive trials. After each trial, a participant is asked to recall the words that were read to them. The number of words recalled on each trial is summed together to produce a total score. The total score (higher score means a better outcome) is converted to a standardized &quot;T&quot; score using normative data. The possible &quot;T&quot; score for each participant ranges from 20 to 80, with higher scores indicative of a better outcome.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Organic Memory Impairment</condition>
  <arm_group>
    <arm_group_label>Memantine, Then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first received Memantine 10 mg capsule twice a day for 24 weeks. After a washout period of 4 weeks, they then received Placebo capsule (matching Memantine 10 mg capsule) twice a day for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Then Memantine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first received Placebo capsule (matching Memantine 10 mg capsule) twice a day for 24 weeks. After a washout period of 4 weeks, they then received Memantine 10 mg capsule twice a day for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine 10 mg capsule</intervention_name>
    <description>Memantine oral capsule was initiated at 5 mg/day at Randomization (Week 0), then titrated to 5 mg twice a day at Week 2, then increased to 10 mg in the morning and 5 mg in the evening at Week 3, and then to 10 mg twice a day (intervention dose) at Weeks 4-24. For the participants in the &quot;Placebo, then Memantine&quot; arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52).</description>
    <arm_group_label>Memantine, Then Placebo</arm_group_label>
    <arm_group_label>Placebo, Then Memantine</arm_group_label>
    <other_name>Namenda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine-matched Placebo capsule</intervention_name>
    <description>Memantine-matched oral Placebo capsule was initiated at Randomization (Week 0) and maintained Weeks 0-24 in a manner consistent with the active drug titration schedule. The number of placebo capsules matched the number of active drug capsules at each titration checkpoint. For the participants in the &quot;Memantine, then Placebo&quot; arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52).</description>
    <arm_group_label>Memantine, Then Placebo</arm_group_label>
    <arm_group_label>Placebo, Then Memantine</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of any chronic medical condition requiring treatment with oral
             corticosteroids confirmed by chart review and/or patient assessment by Dr. Khan
             (co-I).

          -  Receiving prednisone therapy of at least 5 mg of prednisone/day for at least 6 months
             with anticipated treatment for ≥ 12 additional months.

          -  Age 18-65 years.

          -  Baseline CVLT-II total T score ≤ 54.

        Exclusion Criteria:

          -  Illnesses associated with CNS involvement (e.g., seizures, brain tumors, head injury
             with loss of consciousness) or cognitive impairment (e.g., substance dependence within
             the past 2 years, bipolar disorder) Potential participants with mood symptoms
             secondary to corticosteroids (based on SCID) will not be excluded because this could
             selectively exclude subjects who are sensitive to the CNS effects of corticosteroids.

          -  Vulnerable populations (e.g. severe cognitive impairment, pregnant or nursing women,
             prisoners).

          -  Severe or life-threatening medical illness that would make completion of study
             unlikely

          -  Contraindications to memantine therapy (e.g. severe side effects in the past)

          -  Danger to self or others as defined by &gt; 1 lifetime suicide attempt or assault, any
             suicide attempt or assault within the past year, and active suicidal or homicidal
             ideation with plan and intent.

          -  Metal implants, claustrophobia, or other contraindications to MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherwood Brown, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aston Ambulatory Care Center, Allergy and Immunology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8872</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>July 31, 2012</study_first_submitted>
  <study_first_submitted_qc>July 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2012</study_first_posted>
  <results_first_submitted>January 9, 2019</results_first_submitted>
  <results_first_submitted_qc>March 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 29, 2019</results_first_posted>
  <last_update_submitted>March 28, 2019</last_update_submitted>
  <last_update_submitted_qc>March 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>memantine</keyword>
  <keyword>cognition</keyword>
  <keyword>corticosteroid</keyword>
  <keyword>prednisone</keyword>
  <keyword>memory</keyword>
  <keyword>hippocampus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>73 patients were screened for eligibility between May 2012 and January 2016.</recruitment_details>
      <pre_assignment_details>46 of 73 participants were randomized. Of those not randomized, 27 did not meet inclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Memantine, Then Placebo</title>
          <description>Participants first received Memantine 10 mg capsule twice a day for 24 weeks. After a washout period of 4 weeks, they then received Placebo capsule (matching Memantine 10 mg capsule) twice a day for 24 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Then Memantine</title>
          <description>Participants first received Placebo capsule (matching Memantine 10 mg capsule) twice a day for 24 weeks. After a washout period of 4 weeks, they then received Memantine 10 mg capsule twice a day for 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (24 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (24 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Memantine, Then Placebo</title>
          <description>Participants received Memantine 10 mg capsule twice/day for 24 weeks, then underwent a 4-week washout period, then received memantine-matched placebo capsule twice/day for 24 weeks.
Memantine oral capsule was initiated at 5 mg/day at Week 0, then titrated to 5 mg twice/day at Week 2, then increased to 10 mg in the morning and 5 mg in the evening at Week 3, and then to 10 mg twice/day at Weeks 4-24. For the participants in the &quot;Placebo, then Memantine&quot; arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52).
Memantine-matched oral Placebo capsule was initiated at Week 0 and maintained Weeks 0-24 in a manner consistent with the active drug titration schedule. The number of placebo capsules matched the number of active drug capsules at each titration checkpoint. For the participants in the &quot;Memantine, then Placebo&quot; arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52).</description>
        </group>
        <group group_id="B2">
          <title>Placebo, Then Memantine</title>
          <description>Participants received Placebo capsule (matching Memantine 10 mg capsule) twice/day for 24 weeks. After a washout period of 4 weeks, they received Memantine 10 mg capsule twice a day for 24 weeks.
Memantine oral capsule was initiated at 5 mg/day at Week 0, then titrated to 5 mg twice a day at Week 2, then increased to 10 mg in the morning and 5 mg in the evening at Week 3, and then to 10 mg twice a day (intervention dose) at Weeks 4-24. For the participants in the &quot;Placebo, then Memantine&quot; arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52).
Memantine-matched oral Placebo capsule was initiated at Week 0 and maintained Weeks 0-24 in a manner consistent with the active drug titration schedule. The number of placebo capsules matched the number of active drug capsules at each titration checkpoint. For the participants in the &quot;Memantine, then Placebo&quot; arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.10" spread="12.07"/>
                    <measurement group_id="B2" value="43.42" spread="12.72"/>
                    <measurement group_id="B3" value="43.28" spread="12.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hopkins Verbal Learning Test-Revised (HVLT-R) Total Score</title>
        <description>Hopkins Verbal Learning Test-Revised (HVLT-R) is a word memory test that contains 12 nouns that are read to a participant for three consecutive trials. After each trial, a participant is asked to recall the words that were read to them. The number of words recalled on each trial is summed together to produce a total score. The total score (higher score means a better outcome) is converted to a standardized &quot;T&quot; score using normative data. The possible &quot;T&quot; score for each participant ranges from 20 to 80, with higher scores indicative of a better outcome.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>All participants who received at least one dose of each intervention and completed all study visits were included in the analysis. Participants who dropped out during the washout period (between Weeks 24-28) did not receive the second intervention and were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Memantine</title>
            <description>Participants who received Memantine 10 mg capsule twice per day in either the first or last 24 weeks of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received placebo capsule (matching Memantine 10 mg) twice per day in either the first or last 24 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Hopkins Verbal Learning Test-Revised (HVLT-R) Total Score</title>
          <description>Hopkins Verbal Learning Test-Revised (HVLT-R) is a word memory test that contains 12 nouns that are read to a participant for three consecutive trials. After each trial, a participant is asked to recall the words that were read to them. The number of words recalled on each trial is summed together to produce a total score. The total score (higher score means a better outcome) is converted to a standardized &quot;T&quot; score using normative data. The possible &quot;T&quot; score for each participant ranges from 20 to 80, with higher scores indicative of a better outcome.</description>
          <population>All participants who received at least one dose of each intervention and completed all study visits were included in the analysis. Participants who dropped out during the washout period (between Weeks 24-28) did not receive the second intervention and were not included in the analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HVLT Total Score at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.40" spread="1.82"/>
                    <measurement group_id="O2" value="36.93" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HVLT Total Score at 24 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.67" spread="1.61"/>
                    <measurement group_id="O2" value="38.37" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks for each intervention.</time_frame>
      <desc>The safety population included all participants who received at least one dose of intervention.</desc>
      <group_list>
        <group group_id="E1">
          <title>Memantine</title>
          <description>Participants who received Memantine 10 mg capsule twice per day for 24 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants who received Placebo capsule (matching Memantine 10 mg capsule) twice per day for 24 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>C. difficile</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Shingles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lumbar spine injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Gout flare</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Right shoulder pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Vulvar squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Fournier’s gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lupus flare</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated blood glucose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal stool color</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated blood pressure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Low blood pressure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>E. Sherwood Brown, MD, PhD</name_or_title>
      <organization>UT Southwestern Medical Center</organization>
      <phone>214-645-6950</phone>
      <email>sherwood.brown@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

